Estrella Immunopharma receives Nasdaq bid price deficiency notice for ESLA

Estrella Immunopharma, Inc.

Nasdaq notified on Aug 17, 2026 that ESLA bid price stayed below $1.00 for 30 straight days (Jul 6–Aug 14).
Company has until Feb 16, 2027 (180-day period) to regain compliance via 10 consecutive days at $1.00+.
Reverse stock split, if used, must be completed by at least 10 business days before compliance deadline.
If not cured, possible second 180-day extension or delisting appeal; no immediate impact on listing/trading.
Management evaluating options to regain bid price compliance; no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.